Can-fite Biopharma (CANF) Fundamental Analysis: Revenue, Earnings & Valuation

2.29 / 10

Underperform

Fundamentals are underwhelming (2.3/10). Revenue fell ~40% YoY, cost of sales high at 64%, while liquidity ratios are decent and interest coverage strong. Overall, financial health is weak.

Analysis Checks(4/7)

Total operating revenue (YoY growth rate %)

Value-39.91

Score1/3

Weight8.94%

1M Return-0.38%

Inventory turnover ratio

Value103.94

Score2/3

Weight26.03%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value69.63

Score2/3

Weight-8.82%

1M Return0.36%

Long-term debt to working capital ratio (%)

Value0.18

Score1/3

Weight15.34%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight26.46%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-39.91

Score1/3

Weight7.02%

1M Return-0.30%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight25.02%

1M Return-1.13%

Is CANF undervalued or overvalued?

CANF scores 2.29/10 on fundamentals and holds a Premium valuation at present. Backed by its -178.24% ROE, -2426.67% net margin, -0.67 P/E ratio, 1.18 P/B ratio, and 45.03% earnings growth, these metrics solidify its Underperform investment rating.